Last updated on: 12/11/2021
Name of organisation
1) Department/Research group
2) Organisation/affiliationIQVIA
Short Name in the inventoryIQVIA
Administrative Contact
Title Dr
Last name Toussi
First name Massoud
Address line 1Tour D2
Address line 217 bis Place des Reflets
Address line 3
CityCourbevoie
Postcode92090
CountryFrance
Phone number (incl. country code)
Alternative phone number
Fax number (incl. country code)
Scientific Contact
Title Dr
Last name Toussi
First name Massoud
Address line 1Tour D2
Address line 217 bis Place des Reflets
Address line 3
CityCourbevoie
Postcode92090
CountryFrance
Phone number (incl. country code)
Alternative phone number
Fax number (incl. country code)
2. Description
We share the vision to drive healthcare forward. To see how we can help accelerate progress and achievements. It’s bigger than better clinical trials. Or advances in technologies and analytics. Or faster insights. It’s about exploring a new path to better health outcomes via Human Data Science.
Our global scientific, RWE and operational experts are developing innovative methods for RWE study design and execution combining secondary and primary data directly from patients and physicians. Applications include
Post-authorization safety studies (PASS)
Post-authorization effectiveness studies (PAES)
Drug Utilization studies (DUS)
Risk Evaluation and Mitigation Strategy (REMS)
EU Risk Management Plan
Pregnancy Registries
Vaccine
3. Category
For profit organisation
4. Available resources
In houseVia Contacts/Network
Epidemiologist/Pharmacoepidemiologist
Yes
Yes
Statistician
Yes
Yes
Clinician
Yes
Yes
Clinical Pharmacologist
Yes
Yes
Pharmacist
Yes
Yes
Geneticist/Pharmacogeneticist
Yes
Yes
IT specialist
Yes
Yes
Ethics expertise
Yes
Yes
Legal expertise
Yes
Yes
Regulatory expertise
Yes
Yes
AI Specialist
Yes
Yes
Health technology assessment specialist
Yes
Yes
Social media and NLP specialist
Yes
Yes
5. Therapeutic/disease areas of research in drug safety/risk-benefit performed in the past 5 years
Anaesthesia
Cardiovascular diseases
Congenital Malformations
Devices
Disorders of the central nervous system
Ear, nose and oropharynx disorders
Endocrine disorders
Eye disorders
Gastrointestinal tract
Geriatrics
Gynaecology
Immunological products and vaccines
Immunosuppression
Infectious diseases
Liver disease
Malignant disease
Musculoskeletal and joint diseases
Neonates
Nutrition and blood
Osteoporosis
Paediatrics
Poisoning/Overdose
Pregnancy
Psychiatry
Renal impairment
Respiratory diseases
Skin disorders
Urinary tract disorders
Genetics
6. Design of drug safety/risk-benefit studies published in the past 5 years
Cohort Study
Case Control Study
Drug Utilisation
Interventional Clinical Trial
Meta-Analysis
7. Experience in collecting data directly from individual patients/respondents
Number of Studies
Greater than 5
Number of patients/respondents involved in the study(ies)
Less than 150
Between 150 and 1499
Between 1500 and 14999
8. Access to data collection resources
Capacity to conduct face-to-face interviews
Yes
In a clinic
Yes
In the community
Yes
Electronic data capture systems
Yes
System used:
INES
Interactive voice response systems
Yes
Call centre
Yes
9. Experience in secondary research and meta-analysis
Yes
10. Work with existing data resources in the past 3 years
Name of data resourceNo. of studies
Longitudinal Prescription Data(LRx) -France10
IMS LifeLink: PharMetrics Plus - US10
IMS LifeLink:Longitudinal Prescription Data-Spain10
IMS LifeLink: Dx data - US10
THIN10
11. Registries established by centre
Drug RegistrySeveral, industry sponsored
Disease RegistrySeveral, industry sponsored
Other Registries built on top of EMRs
12. Experience in collaboration in a study team
Principal Investigator
Collaborating Investigator
13. Current involvement in research networks
Other networks:
Network nameNationalInternationalLink to webpage
Research consortium for oral retinoids
No
Yes
Research consortium for valproate compounds
No
Yes
Research consortium for trimetazidine compounds
No
Yes
Research consortium for thiocholchicoside compounds
No
Yes
14. Interest in research opportunities which are funded
By pharmaceutical companies
By charities
By government
By research councils
By EU funding schemes
15. Interest in contract research only if free to publish results
Yes
16. Selected publications of the last 5 calendar years
ReferenceLink to web-publication
Concordance with prescribing information dosage recommendations for dipeptidyl-peptidase-4 inhibitors among type 2 diabetes mellitus patients with moderate to severe chronic kidney disease.https://www.ncbi.nlm.nih.gov/pubmed/29231750
